Brian M. Gallagher

Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose.

Brian M. Gallagher, Joanna S. Fowler, Neal Gutterson et al. · PubMed · 1978 · 560 citations

Metabolic Remodeling, Metabolic Trapping, Metabolic Model +22

Radiopharmaceuticals XXVII. 18F-labeled 2-deoxy-2-fluoro-d-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals.

Brian M. Gallagher, A.N. Ansari, H.L. Atkins et al. · Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) · 1977 · 205 citations

A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models

Vijaykumar M. Baragi, Gabriele Becher, Alison M. Bendele et al. · Arthritis & Rheumatism · 2009 · 171 citations

Measurement of local cerebral glucose metabolism in man with 18F-2-fluoro-2-deoxy-d-glucose.

M. Reivich, Dietmar Kuhl, A.P. Wolf et al. · PubMed · 1977 · 121 citations

Neurophysiology, Physiology, Blood Glucose Monitoring +8

Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts.

Howard Sands, Peter L. Jones, Sudhir Shah et al. · PubMed · 1988 · 119 citations

Immunocytochemical Technique, Renal Pathology, Immunology +16